An Act relative to benzodiazepines and non-benzodiazepine hypnotics
House: Accompanied a study order, see H5319 (under House Rule 27)
Email me when H 2223 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track H 2223. By continuing you agree to the Terms and Privacy Policy.
Summary
The bill adds definitions for benzodiazepines and non‑benzodiazepine hypnotics, mandates bold warning labels on prescriptions, and requires pharmacists to give patients informational pamphlets. It also bars refills for prescriptions under ten days, obliges doctors to obtain written informed consent, and creates a commission to study safe discontinuation protocols. The aim is to curb misuse and improve patient safety.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about H 2223
3 free questions a day, no accountHearings
- Treatment Settings and PsychedelicsJoint Committee on Mental Health, Substance Use and Recovery · Nov 10, 2025
History
- Accompanied a study order, see H5319 (under House Rule 27)
- Hearing scheduled for 11/10/2025 from 01:00 PM-05:00 PM in A-2
- Senate concurred
- Referred to the committee on Mental Health, Substance Use and Recovery
Sponsors
- Paul McMurtry · sponsor
- Michael P. Kushmerek
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when H 2223 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track H 2223 freeOr ask your AI assistant about H 2223 directly:
Add to Claude, ChatGPT or Cursor